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Abstract
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the leading inheritable cause of end-stage
renal disease (ESRD); however, the natural course of disease progression is heterogeneous between patients. This study
aimed to develop a natural history model of ADPKD that predicted progression rates and long-term outcomes in patients
with differing baseline characteristics.
Methods: The ADPKD Outcomes Model (ADPKD-OM) was developed using available patient-level data from the placebo
arm of the Tolvaptan Efficacy and Safety in Management of ADPKD and its Outcomes Study (TEMPO 3:4; ClinicalTrials.gov
identifier NCT00428948). Multivariable regression equations estimating annual rates of ADPKD progression, in terms of
total kidney volume (TKV) and estimated glomerular filtration rate, formed the basis of the lifetime patient-level simulation
model. Outputs of the ADPKD-OM were compared against external data sources to validate model accuracy and
generalisability to other ADPKD patient populations, then used to predict long-term outcomes in a cohort matched to
the overall TEMPO 3:4 study population.
Results: A cohort with baseline patient characteristics consistent with TEMPO 3:4 was predicted to reach ESRD at a mean
age of 52 years. Most patients (85%) were predicted to reach ESRD by the age of 65 years, with many progressing to
ESRD earlier in life (18, 36 and 56% by the age of 45, 50 and 55 years, respectively). Consistent with previous research and
clinical opinion, analyses supported the selection of baseline TKV as a prognostic factor for ADPKD progression, and
demonstrated its value as a strong predictor of future ESRD risk. Validation exercises and illustrative analyses confirmed
the ability of the ADPKD-OM to accurately predict disease progression towards ESRD across a range of clinically-relevant
patient profiles.
Conclusions: The ADPKD-OM represents a robust tool to predict natural disease progression and long-term outcomes in
ADPKD patients, based on readily available and/or measurable clinical characteristics. In conjunction with clinical
judgement, it has the potential to support decision-making in research and clinical practice.
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Background
Autosomal dominant polycystic kidney disease (ADPKD)
is the most common monogenic kidney disease, and the
leading inheritable cause of end-stage renal disease
(ESRD) among adults [1, 2]. The disease arises from
genetic mutations in PKD1 (85% of cases) and PKD2
(15% of cases), which cause progressive bilateral renal
cyst formation, kidney enlargement, fibrosis, chronic
kidney disease (CKD) and renal failure. While ADPKD
may present in utero and during childhood, early-stage
disease is often asymptomatic and undiagnosed due to
compensatory glomerular hyperfiltration [1, 3]. In later
stages of ADPKD, the irreversible loss of functional
glomeruli exhausts compensatory mechanisms, leading to
a detectable decline in glomerular filtration rate (GFR)
during the third and fourth decades of life [1, 3, 4]. The
natural course of ADPKD towards renal failure is hetero-
geneous between patients and variable over time; however,
the average age at which patients commence renal
replacement therapy (RRT) for progressive disease falls
between 55 and 60 years across European countries [5, 6].
The social and economic burden of ADPKD on patients
and healthcare systems is largely driven by the incurable
deterioration of kidney function, and the provision of RRT
to patients who ultimately progress to ESRD [1, 2, 7].
Early identification of ADPKD patients with rapidly
progressing disease may facilitate the selection of those
most likely to benefit from treatment in clinical trials and
clinical practice; thus, improving the cost-effectiveness
and benefit-to-risk ratio of novel therapies in a population
with high unmet need [1, 8, 9]. A systematic literature
review by Woon et al. identified age at diagnosis and total
kidney volume (TKV) as the most commonly cited
prognostic indicators associated with rapid ADPKD
progression [10]; additional factors reported in the
literature include baseline GFR, male gender and PKD1
mutation [1, 3, 10].
Until recently, treatment strategies for ADPKD were
limited to managing its clinical manifestations of hyper-
tension, pain, urinary tract infection, and kidney stones.
In 2015, tolvaptan (a selective vasopressin V2 receptor
antagonist) received marketing authorisation from the
European Medicines Agency (EMA), to delay ADPKD
progression in adults with CKD stage 1–3 and evidence
of rapidly progressing disease [11]. Recommendations by
the European Renal Association-European Dialysis and
Transplant Association (ERA-EDTA) include a hierarch-
ical treatment algorithm to identify those rapidly pro-
gressing patients most likely to benefit from tolvaptan,
based on estimated GFR (eGFR) decline, documented
TKV growth and other clinical factors [8].
Clinical evidence that informed EMA and ERA-EDTA
guidance was derived from the phase 3, double-blind,
placebo-controlled Tolvaptan Efficacy and Safety in
Management of Autosomal Dominant Polycystic Kidney
Disease and Its Outcomes trial (TEMPO 3:4; Clinical-
Trials.gov identifier NCT00428948) [12]. The clinical
effectiveness of tolvaptan was evaluated using study
endpoints of TKV (measured using a gold-standard
magnetic resonance imaging protocol) and eGFR, which
are established determinants of ADPKD progression and
kidney function, respectively [8, 13]. Data was collected
from 1445 patients across 129 international sites over 3
years; thus, TEMPO 3:4 represents one of the largest
sources of high-quality patient-level data currently
available in the field of ADPKD.
The development of therapies that delay ADPKD
progression drive the requirement for resources that
identify patients eligible for treatment and optimise
clinical decision-making. Since early-stage ADPKD is
largely undiagnosed, and disease progression towards
ESRD is heterogeneous and prolonged over several de-
cades, the size and length of clinical trials in ADPKD are
insufficient to capture the natural history of the disease
[10]. Alternatively, simulation modelling can predict dis-
ease progression over time horizons longer than that
feasible in clinical trials, and may therefore represent a
useful tool to model the natural rate of renal decline,
particularly when measurable and/or observable patient
characteristics are used as inputs. Using patient-level
data from the placebo arm of TEMPO 3:4, the aim of
the present study was to develop and validate a natural
history model that simulated disease progression accord-
ing to this principle, and predicted long-term outcomes
across a range of ADPKD patient profiles.
Methods
ADPKD progression equations
To identify relationships between TKV, eGFR and available
patient risk factors, exploratory analysis of patient-level data
from the TEMPO 3:4 placebo arm (Table 1) was conducted
using R version 2.12.2. Candidate prognostic variables
assessed within a multivariable regression framework
included those identified in the literature [10], agreed upon
by clinical experts in ADPKD management, and available
within the TEMPO 3:4 dataset: baseline age, gender, child
bearing age, ethnicity, region, country, TKV (analysed at
baseline, 12, 24 and 36 months) and eGFR (analysed at
corresponding timepoints). Candidate variables were
entered into the model simultaneously, and the step AIC
approach [14] was used to identify candidate models and
test for interactions between covariates.
Selected covariates were incorporated within a two-
step statistical model that predicted annual changes in
TKV (Eq. 1) and eGFR (Eq. 2), based on statistical
significance and clinical relevance. A natural log
transformation was applied, where it provided a better
fit and improved regression diagnostics. Subsequently,
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multivariable regression equations were fitted to mean
annual changes in TKV + 500 and eGFR + 60, to avoid
taking the natural log of a negative number.
Renal function in TEMPO 3:4 was assessed using two
measures of eGFR [12]. The secondary study endpoint
was the change in kidney function according to the re-
ciprocal of serum creatinine, while eGFR based on the
Chronic Kidney Disease Epidemiology Collaboration
(CKD-Epi) equation [15] was used to ascertain CKD
stage at baseline, in line with clinical guidelines [13]. In
the present study, changes in eGFR were modelled based
on the reciprocal of serum creatinine data from TEMPO
3:4. However, the impact of using CKD-Epi equation es-
timates of GFR to fit the coefficients of the eGFR
progression equation was additionally assessed in sensi-
tivity analysis (Additional file 1).
Eq. 1 Annual change in TKV equation implemented
within the ADPKD-OM
ΔTKV ¼ exp

λþ α:ageþ β:LnðTKVtÞ
þγ:femaleþ δ:age:Ln TKVð Þ−500
ð1Þ
TKV, total kidney volume; ΔTKV, 1-year change in
TKV; α, age coefficient; β, TKV coefficient; γ, female coef-
ficient; δ, age:LnTKV coefficient; λ, intercept.
Eq. 2 Annual change in eGFR equation implemented
within the ADPKD-OM
ΔeGFR ¼ exp λþ β:Ln TKVð Þ½ −60 ð2Þ
eGFR, estimated glomerular filtration rate; ΔeGFR, 1-
year change in eGFR; TKV, total kidney volume; β,
Ln(TKV) coefficient; λ, intercept.
ADPKD Outcomes Model
Disease progression equations formed the basis of the
ADPKD Outcomes Model (ADPKD-OM); a fixed-time
increment stochastic simulation model, implemented in
Microsoft Excel and coded in Visual Basic for Applica-
tions. The ADPKD-OM conducted patient-level simula-
tions to predict the natural history of ADPKD, and
aggregated estimates across a hypothetical cohort of up
to 10,000 patients. For each year of the simulated time
horizon, disease progression equations predicted the
natural course of ADPKD progression and produced
non-linear trajectories of TKV and eGFR. Simulated
patients progressed through the model over a maximum
horizon of 80 years (i.e. lifetime); from baseline, between
CKD stages, and until the onset of ESRD (eGFR
<15 mL/min/1.73 m2) or death, whichever occurred first
(Fig. 1). All-cause mortality was modelled according to
gender-specific life tables obtained from the UK Office
for National Statistics [16]. Key outputs of the ADPKD-
OM, reported across the simulated cohort, included the
incidence of ESRD (over a lifetime horizon or by a pre-
defined age), average age at ESRD onset, and distribution
of time spent across CKD stages.
Uncertainty in model predictions of ADPKD progression
was accounted for; thus, patients with the same baseline
characteristics could incur different TKV and eGFR trajec-
tories, reflective of natural inter-patient variability. This was
achieved by sampling the ADPKD progression equation
coefficients from multivariable normal distributions, using
variance covariance matrices associated with each regres-
sion equation (Additional file 1: Tables S1 and S2).
Model validation
External validation exercises tested the accuracy of
the ADPKD-OM to predict natural disease progres-
sion, and investigate the generalisability of its predic-
tions to alternative ADPKD patient populations. In
the absence of a lifetime study of ADPKD patients,
model predictions were validated against alternative
study cohorts that differed with respect to patient
characteristics, disease stage and rate of progression.
Briefly, ADPKD-OM progression equations were first
compared against those derived from annual TKV and
eGFR changes observed in the Consortium for Radio-
logic Imaging Studies of Polycystic Kidney Disease
(CRISP I) study, a population not fully enriched for
patients with rapidly progressing ADPKD [17, 18].
Modelled trajectories of TKV and eGFR were then
compared against the results of the Halt Progression
of Polycystic Kidney Disease (HALT-PKD) studies, to
validate ADPKD-OM predictions in patients with
early-stage (Study A) and late-stage ADPKD (Study B)
[19, 20]. To further validate the ADPKD-OM in pa-
tients with late-stage disease in clinical practice,
Table 1 Baseline patient characteristics (post-randomisation)
and changes in TKV and eGFR, as observed in the placebo arm
of TEMPO 3:4 study [12, 39]
Placebo arm
(N = 484)
Male gender (n, %) 251 (51.9)
TKV (mL)
Baseline (mean, SD) 1667.5 (873.1)
Annual change
(mean, SD)
114.4 (113.2)
eGFRa 1/SC ([mg/mL]−1) CKD-Epi (mL/min/1.73 m2)
Baseline (mean, SD) 104.30 (33.87) 82.14 (22.73)
Annual change
(mean, SD)
−3.682 (6.361) −3.568 (4.495)
1/SC reciprocal of serum creatinine, CKD-Epi Chronic Kidney Disease
Epidemiology Collaboration, eGFR estimated glomerular filtration rate, SD
standard deviation, TKV total kidney volume
aeGFR was measured using both the reciprocal of serum creatinine (1/SC) and
Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equation [12]
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simulated eGFR trajectories were compared against
observed data for 64 patients selected from The
Health Improvement Network (THIN) database, over
6 years prior to ESRD [21]. Further details of the
model validation exercises performed in this study are
described in Additional file 1.
Model application
Following validation, the ADPKD-OM was used to
simulate disease progression in a hypothetical cohort
with baseline characteristics matched to the overall
TEMPO 3:4 study population (Table 2). The underlying
variability of disease progression was assessed by simu-
lating individual patients drawn from a cohort with the
described baseline characteristics, to report standard
deviations (SD) and interquartile range (IQR). Baseline
characteristics and regression equation coefficients were
sampled in all analyses.
To assess the influence of baseline characteristics on
model predictions, the ADPKD-OM was used to predict
age at ESRD onset for hypothetical patient cohorts with
varying baseline age (25–45 years), eGFR (60–110 mL/min/
1.73 m2) and TKV (1000–2000 mL). Univariate sensitivity
analyses were additionally performed to independently
explore the impact of baseline age (± 10 years), eGFR (±
20%), TKV (± 20%) and gender (0–100% female) on
predicted outcomes, using illustrative cohorts with increas-
ingly advanced stages of ADPKD progression at baseline.
Illustrative analysis
The ADPKD-OM was used to simulate disease progres-
sion in three real-world clinical examples: a “rapidly
progressing patient” as per ERA-EDTA recommenda-
tions [8], with high TKV and low eGFR; a “young
patient”, with large kidneys for their age; and an “older
patient with preserved renal function”. Baseline profiles
of each hypothetical cohort were defined in terms of
clinical characteristics that drive prediction of disease
progression in the ADPKD-OM (age, gender, TKV and
eGFR), in addition to descriptive characteristics that may
be associated with these predictive risk factors.
Results
ADPKD progression equations
Age, gender and TKV were selected as covariates to model
annual changes in TKV and eGFR within the ADPKD-
OM. Tables 3 and 4 present the coefficient estimates for
the TKV and eGFR progression equations, respectively;
associated variance covariance matrices are provided in
Additional file 1 (Tables S1 and S2). An example of using
Fig. 1 Flow diagram of patient simulation through the ADPKD Outcomes Model. CKD: chronic kidney disease; eGFR: estimated glomerular filtration
rate; ESRD: end-stage renal disease; TKV: total kidney volume
Table 2 Baseline characteristics (mean ± SD) of the TEMPO 3:4
study cohort [12, 24, 39]
Characteristic Placebo arm
(N = 484)
Treatment arm
(N = 961)
Overall
(N = 1445)
Male, no. (%) 251 (51.9) 495 (51.5) 746 (51.6)
Age (years) 39 ± 7 39 ± 7 38.7 ± 7.1
TKV (mL) 1668 ± 873 1705 ± 921 1692 ± 905
eGFR (mL/min/1.73 m2)a 82.14 ± 22.73 81.35 ± 21.02 81.61 ± 21.60
CKD chronic kidney disease, eGFR estimated glomerular filtration rate, TKV total
kidney volume
aBaseline eGFR was based on the Chronic Kidney Disease Epidemiology
Collaboration (CKD-Epi) equation [15], used to ascertain CKD stage at baseline
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the disease progression equations to calculate annual TKV
growth and eGFR decline in a hypothetical ADPKD
patient is also provided in Additional file 1.
Consistent with published literature and clinical opin-
ion, patient-level analysis of TEMPO 3:4 data supported
the selection of age and baseline TKV as predictive risk
factors for annual TKV growth, with positive coefficient
estimates relating increased rate of TKV growth with
advancing age and larger kidneys. A negative coefficient
value for the interaction term between age and baseline
TKV indicated that the relative impact of TKV on disease
progression decreased over time. Despite not reaching a
conventional level of significance (p = 0.0684), gender was
additionally selected as a predictive risk factor of TKV
growth, due to its recognised correlation with height-
adjusted TKV (an alternative prognostic indicator not
available in the TEMPO 3:4 dataset).
Patient-level analysis similarly supported the selection
of current TKV as a predictive risk factor for annual
eGFR decline, with a negative coefficient estimate relat-
ing larger kidneys to an increased rate of eGFR decline.
Additional sensitivity analyses demonstrated that the
impact of using CKD-Epi measurements to fit the coeffi-
cients of the eGFR progression equation was minimal
(Additional file 1: Tables S3 and S4; Additional file 2:
Figure S1).
Model validation
Predicted trajectories of disease progression from the
ADPKD-OM were consistent with predictions derived
from equations fitted to CRISP I data for eGFR (Fig. 2a)
and TKV (Additional file 3: Figure S2). As the CRISP I
study population was not fully enriched for patients with
rapidly progressing ADPKD, 95% prediction intervals
were found to widen over time.
Model predictions were also consistent with the results
of both HALT-PKD trials. Using baseline characteristics
from early-stage patients in Study A, the ADPKD-OM
predicted annual eGFR (Fig. 2b) and TKV (Add-
itional file 4: Figure S3) measurements within the 95%
confidence interval of trial observations. Validation
against late-stage patients in HALT-PKD Study B was
complicated by the lack of TKV data and a reduction in
eGFR decline toward study end, likely due to attrition of
participants with rapid renal progression [20]. Neverthe-
less, ADPKD-OM predictions closely replicated the trial
observations after adjustment for this potential survivor
effect from year 4 onwards, when a baseline TKV of
1000–1500 mL was modelled (Fig. 2c). Approximate
average annual slopes predicted for baseline TKV of
1000 mL and 1500 mL were −3.2 and −4.4 mL/min/
1.73 m2, respectively, compared with −3.9 mL/min/
1.73 m2 reported in the trial.
To further validate late-stage ADPKD patients, eGFR
predictions from the ADPKD-OM were compared with
observational patient-level data from the THIN database
for 64 patients, over 6 years prior to ESRD. Predicted
trajectories were consistent with observed data, with a
modelled baseline TKV of 1500 mL achieving the best
fit (Fig. 2d).
Model application
In a simulated cohort consistent with the rapidly
progressing TEMPO 3:4 population at baseline, the
mean age at ESRD onset was predicted to be
52.4 years (median 53.4; IQR 47.1–60.1; SD 10.0).
Prior to ESRD, modelled ADPKD patients spent a
mean of 13.6 years in CKD stages 1–4 (median 13.9;
IQR 10.9–17.4; SD 6.8), with 5.6, 5.4 and 2.5 years
spent in CKD stages 2, 3 and 4, respectively. It was
predicted that 98% of the simulated cohort would
progress to ESRD over a lifetime. Most of the
modelled cohort reached ESRD prior to the age many
individuals retire (62–67 years across European coun-
tries), with a substantial proportion progressing earlier
in life: 18, 36, 56, 73 and 85% by the age of 45, 50,
55, 60 and 65 years, respectively.
Figure 3 demonstrates the influence of baseline patient
characteristics on ADPKD-OM predictions of disease
progression. Baseline age had a modest impact on age at
Table 3 Coefficient estimates for the TKV progression equation (Eq. 1), as derived from TEMPO 3:4 patient-level TKV data
Coefficient estimate SE t value Pr(>|t|)
Intercept (λ) 0.7889 1.1313 0.697 0.4860
Age (years) (α) 0.1107 0.0287 3.858 0.0001
Ln(Baseline TKV) (β) 0.8027 0.1556 5.159 0.0000
Sex (female = 1, male = 0) (γ) −0.0486 0.0266 −1.827 0.0684
Age:Ln(Baseline TKV) (δ) −0.0160 0.0039 −4.058 0.0001
SE standard error, TKV total kidney volume
Table 4 Coefficient estimates for the eGFR progression equation
(Eq. 2), as derived from TEMPO 3:4 patient-level reciprocal of serum
creatinine measurements
Coefficient estimate SE t value Pr(>|t|)
Intercept (λ) 4.48474 0.08244 54.398 <0.0001
Ln(TKV) (β) −0.06227 0.01124 −5.539 <0.0001
SE standard error, TKV total kidney volume
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ESRD onset among simulated cohorts with the same
renal characteristics (eGFR and TKV), with patients aged
45 years at baseline reaching ESRD up to 3.1 years later
than those aged 25 years. In comparison, the relation-
ship between baseline TKV and age at ESRD was more
pronounced and evident across all baseline age groups;
and the relative impact of TKV on ESRD onset was
similar across baseline eGFR levels. Thus, patient
cohorts with larger kidneys at a younger age were
predicted to progress to ESRD at an earlier age, with less
variation in predicted outcomes.
The results of univariate sensitivity analyses comparing
the influence of baseline patient characteristics on
predicted long-term outcomes are displayed in Fig. 4. As
cohorts with increasingly advanced ADPKD were simu-
lated, the proportion of patients expected to reach ESRD
increased and the mean predicted time to ESRD onset
decreased. Baseline eGFR was a driver of predicted out-
comes, associated with up to 4% difference in the
probability of lifetime ESRD incidence and up to 8 years'
difference in the time to ESRD onset. However, the like-
lihood of ESRD was most sensitive to baseline age (up to
13% difference), and the mean time to ESRD onset was
also influenced by baseline TKV (up to 7 years’ differ-
ence). By contrast, gender had a comparatively small ef-
fect on predicted outcomes. Across the characteristics
examined, the variation in predicted outcomes consist-
ently decreased with increasingly advanced disease char-
acteristics at baseline.
Illustrative analysis
Figure 5 illustrates ADPKD-OM predictions of disease
progression across three real-world clinical examples.
The model predicted that a “rapidly progressing patient”,
with high TKV and low eGFR, would progress to ESRD
at 49–52 years of age. A “young patient” with large
kidneys for their age was predicted to reach ESRD at age
49–54 years, in contrast to an “older patient with
Fig. 2 Validation of the TEMPO 3:4 disease progression equations implemented within the ADPKD Outcomes Model. Trajectories of eGFR progression
were consistent with predictions derived from equations fitted to CRISP I data (panel a), while model-predicted eGFR progression was consistent with
observed data from HALT-PKD Study A (panel b), HALT-PKD Study B (panel c), and THIN database (panel d). Shaded regions depict 95% prediction
intervals; error bars depict 95% confidence intervals. ADPKD-OM: autosomal dominant polycystic kidney disease Outcomes Model; CRISP: Consortium
for Radiologic Imaging Studies of Polycystic Kidney Disease study; eGFR: estimated glomerular filtration rate; ESRD: end-stage renal disease; HALT-PKD:
Halt Progression of Polycystic Kidney Disease trials; THIN: The Health Improvement Network; TKV: total kidney volume
McEwan et al. BMC Nephrology  (2018) 19:37 Page 6 of 12
preserved kidney function” predicted to progress to
ESRD at age 60–65 years. Relative to the other patient
profiles, the truncated time to ESRD shown by the
“rapidly progressing patient” illustrates the importance
of TKV as a predictor of disease progression.
Discussion
At present ADPKD is an incurable condition, with
patients experiencing heterogeneous rates of progres-
sion towards kidney failure over several decades. As
targeted therapies are developed, there is an increased
need for user-friendly tools that accurately predict the
natural history of ADPKD, and distinguish rapidly
progressing patients most likely to benefit from treat-
ment. To facilitate the timely identification of patients
with greatest unmet need, the present study sought to
develop a simulation model capable of predicting the
long-term risk and rate of progression towards ESRD,
where inputs are limited to readily observable and/or
measurable characteristics of ADPKD patients. After
implementing progression equations derived from
available TEMPO 3:4 trial data, disease progression
estimates generated by the ADPKD-OM were assessed
for clinical plausibility and validated against external
data sources. In combination with clinical judgement,
the ADPKD-OM subsequently represents a valuable
resource to predict the natural history of ADPKD for
research and clinical practice.
The ADPKD-OM generates accurate predictions of
disease progression and long-term outcomes for hypo-
thetical cohorts, with respect to clinical characteristics
that are readily available and/or measurable among
those with ADPKD. Covariates to inform the develop-
ment of TKV and eGFR progression equations were
evaluated based on predictive factors identified in the
literature [1, 3, 8–10, 12, 18, 22] and the opinions of
clinical experts in ADPKD management, and were
selected in conjunction with patient-level analysis of
the TEMPO 3:4 placebo arm. Our analyses supported
the selection of age and baseline TKV as strong
predictive risk factors for annual TKV growth, and
current TKV as a powerful predictive risk factor for
Fig. 3 Age at ESRD onset as a function of baseline patient characteristics: eGFR (60–110 mL/min/1.73 m2); age (25–45 years); TKV (1000–2000 mL).
Midline represents median; upper and lower hinges represent 25th and 75th percentiles; upper and lower whiskers represent highest and lowest
values within 1.5 times the interquartile range; data beyond the whiskers are plotted as outliers. eGFR: estimated glomerular filtration rate; ESRD:
end-stage renal disease; TKV: total kidney volume
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future rate of eGFR decline. The inclusion of gender as
an additional predictor of TKV growth is consistent
with general statistical guidance, in which variables
known to be relevant are retained despite not achieving
a conventional level of significance [23].
In the absence of a lifetime trial or registry of ADPKD
patients, the TEMPO 3:4 trial that informed the
development of ADPKD-OM progression equations
remains to be one of the largest sources of high-quality
patient-level data in this field [12, 24]. The TEMPO 3:4
study population comprised of ADPKD patients aged
≤50 years, with TKV ≥750 mL and an estimated creatine
clearance of ≥60 mL/mL; therefore, by design, TEMPO
3:4 selected for patients with early-stage disease and pre-
served renal function, but with high likelihood of rapid
progression. Since model validity is dependent on the
data used to inform its development, caution is required
when simulating populations that do not conform to the
TEMPO 3:4 cohort profile. However, external validation
exercises demonstrated that ADPKD-OM predictions of
disease progression were credible when alternative pop-
ulations, not enriched for patients with rapid
progression, were simulated. Modelled trajectories of
eGFR and TKV in early-stage ADPKD patients were val-
idated against data derived from CRISP I [18] and
HALT-PKD Study A [19], while model-predicted disease
progression in late-stage disease was consistent with ob-
servations from HALT-PKD Study B [20] and THIN
[21]. Furthermore, the ADPKD-OM was developed in
line with National Institute for Health and Care Excel-
lence (NICE) Decision Support Unit guidance [25] and
was designed, constructed and tested according to good
practice guidelines [26]. Model predictions have under-
gone independent scrutiny as part of health technology
assessments carried out by NICE and the Scottish
Medicines Consortium, and were considered sufficiently
robust to inform health economic decision-making in
ADPKD [27, 28]. As new data in this field becomes
available, ongoing validation and refinement of the
ADPKD-OM will ensure the continued accuracy of
model predictions, and extend its generalisability to
other ADPKD populations in the future.
Simulation of hypothetical patient cohorts within the
validated ADPKD-OM highlighted the burden associated
Fig. 4 Univariate sensitivity analyses demonstrating the influence of baseline patient characteristics on lifetime ESRD risk and predicted age at
ESRD onset. Profiles 1–3 represent hypothetical patient cohorts with increasingly advanced stages of ADPKD progression at baseline. Vertical lines
represent base-case values. eGFR: estimated glomerular filtration rate; ESRD: end-stage renal disease; TKV: total kidney volume
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with ADPKD, and its progression towards ESRD, on
society and public healthcare systems. In a cohort
consistent with the TEMPO 3:4 population at baseline,
the predicted mean age at ESRD onset was 52 years,
with the majority of patients having progressed to ESRD
prior to retirement age (62–67 years across European
countries) [29]. Differences in the mean age at ESRD
predicted by the model compared with estimates in the
literature [2, 5, 6, 10, 22] are reflective of the rapidly pro-
gressing patient population selected as a result of
TEMPO 3:4 eligibility criteria [12, 24]. However, model-
ling disease progression in alternative, real-world clinical
examples similarly demonstrated significant ESRD risk
over the course of a patient’s lifetime. This study
presents the ADPKD-OM as a validated approach to
simulate the natural progression of ADPKD and predict
long-term public health outcomes in the absence of
therapy; an important feature to underpin future appli-
cations of the model. Extending the ADPKD-OM
beyond ESRD onset will enhance the model’s ability to
evaluate fully the long-term burden of ADPKD, predict
patient life expectancy, and quantify outcomes associ-
ated with RRT. Furthermore, the incorporation of costs
and treatment effects will allow the health economic
value of future therapeutic management practices to be
estimated in the absence of long-term clinical evidence.
This study additionally highlighted the influence of
baseline patient characteristics on ADPKD-OM pre-
dictions of disease progression. Analyses demonstrated
the sensitivity of predicted ADPKD progression to
baseline age, TKV and eGFR, and the value of TKV
as an early prognostic factor for future ESRD risk;
findings that are aligned with those of published lit-
erature [3, 10, 18]. Such research has informed the
development of the Mayo classification of ADPKD
[9]; and recommendations issued by the EMA and
the US Food and Drug Administration, which collect-
ively qualify TKV, in combination with patient age
and baseline eGFR, as a prognostic biomarker for
patient selection in clinical trials of ADPKD [30, 31].
In clinical practice, the ERA-EDTA consensus statement
similarly recognises the value of documented eGFR
decline, documented TKV growth and patient age, in
addition to factors such as CKD stage, ADPKD genotype
and family history, to assess the risk of rapid progression
among ADPKD patients [8]. While the ERA-EDTA
Fig. 5 Prediction of disease progression for three illustrative ADPKD patient profiles. Upper sections of patient characteristics describe modelled
drivers of progression. CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; ESRD: end-stage renal disease; TKV: total kidney
volume; PI: prediction interval
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algorithm and Mayo classification system are valuable
tools to evaluate a patient’s likelihood of rapid progression
and eligibility for treatment in clinical research and prac-
tice, the ADPKD-OM provides an additional resource that
communicates long-term risk in terms of predicted age at
ESRD onset.
Although the ADPKD-OM simulates progression
towards ESRD with respect to established drivers of
baseline TKV, eGFR, patient age and gender, it does
not consider additional factors for which data was not
captured during TEMPO 3:4. Consistent with the ap-
proach of other ADPKD progression models [9, 22],
the ADPKD-OM did not account for hypertension
and proteinuria, as the clinical presentation of these
factors is heterogeneous across patients [32, 33]. Simi-
larly, the consequences of extra-renal manifestations,
including polycystic liver disease or cardiovascular
disease, were not modelled due to a lack of published
data on the prevalence of ADPKD-related complica-
tions. The model does not consider differences in
ADPKD progression due to PKD1 or PKD2 mutation
[34, 35]; however, since genotype is a major determin-
ant of baseline TKV [1, 36, 37], the inclusion of TKV
within the model may adequately account for this
limitation. Furthermore, mortality risk in ADPKD pa-
tients prior to ESRD was conservatively assumed to
be consistent with that reported for the general UK
population, due to a lack of ADPKD-specific mortality
data. While this approach may underestimate mortal-
ity and consequently overestimate the percentage of
patients expected to reach ESRD in ADPKD-OM
simulations, predictions of time to ESRD among
patients who progress would not be unduly biased.
Trajectories of disease progression generated by the
ADPKD-OM should be interpreted with its limitations
in mind, and should not replace clinical judgement.
However, in conjunction with clinical assessment and
other predictive algorithms, the ADPKD-OM repre-
sents an informative tool to assess risks and long-
term outcomes in ADPKD patients; and support
decision-making in research and clinical practice. By
simulating hypothetical patient cohorts of varying age,
eGFR and TKV, this study demonstrated the ability of
the ADPKD-OM to accurately predict long-term
disease progression towards ESRD as a function of
observable and/or measurable patient characteristics.
While eGFR and clinical experience of symptoms are
traditionally used to predict disease progression in
clinical assessment, the measurement of renal volume
in ADPKD patients is not yet considered routine
practice. Despite this, validation exercises found that
in the absence of TKV data, disease progression pre-
dicted by the ADPKD-OM remained plausible over a
range of baseline values. As the prognostic value of
TKV growth in ADPKD patients is increasingly recog-
nised and advocated [8, 38], the adoption of this
measure in routine clinical practice will only enhance
predictions of disease progression generated by the
ADPKD-OM.
Conclusions
This study developed a natural history model of
ADPKD, which serves to predict disease progression
and long-term outcomes with respect to characteris-
tics that are readily observable and/or measurable
among ADPKD patients. Simulation of hypothetical
cohorts within the ADPKD-OM demonstrated the
model’s validity when compared against external data
sources; and the sensitivity of its predictions to
baseline age, TKV and eGFR. Irrespective of patient
characteristics, predictions of disease progression in
real-world clinical examples highlighted the potential
long-term burden of ADPKD to society and public
healthcare systems. At present ADPKD is an incur-
able condition that exhibits heterogeneous rates of
disease progression towards ESRD; however, the
ADPKD-OM represents a valuable tool that utilises
available clinical data to identify patients most likely
to benefit from novel therapies in research and
clinical practice.
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